In short
A clinical trial is underway to evaluate the safety and effectiveness of a new drug called PRI-002 for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD). This study aims to assess how well the drug works and if it's safe to use in people with early stages of Alzheimer's. The trial is designed to be randomized, double-blind, and placebo-controlled, which means participants will be randomly assigned to receive either PRI-002 or a placebo, and neither the patients nor the researchers will know who is receiving the actual drug during the study.
At a glance
- Drug Name
- PRI-002
- Drug Type
- Synthetic peptide
- Administration
- Oral capsule
- Target Condition
- Mild Cognitive Impairment (MCI) or mild dementia due to Alzheimer's disease
- Age Range
- 55 to 80 years
- Primary Objectives
- Evaluate safety, tolerability, and efficacy
- Main Efficacy Measure
- Change in Clinical Dementia Rating-Sum of Boxes (CDR-SB)
- Study Duration
- 48 weeks
- Key Assessments
- Cognitive tests, daily living activities, biomarkers in CSF and plasma
What is PRI-002?
PRI-002 is a new drug being studied for the treatment of Alzheimer's disease. It is specifically designed to help patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The drug is a synthetic peptide, which means it's a small protein-like molecule created in a laboratory. Its full chemical name is quite complex: D-PROLYL-D-THREONYL-D-LEUCYL-D-HISTIDYL-D-THREONYL-D-HISTIDYL-D-ASPARAGINYL-D-ARGINYL-D-ARGINYL-D-ARGINYL-D-ARGINYL-D-ARGININE AMIDE ACETATE.
How PRI-002 Works
While the exact mechanism of PRI-002 is not fully explained in the provided information, it's important to understand that Alzheimer's disease is associated with the buildup of abnormal proteins in the brain, particularly amyloid-beta (Aβ) and tau. PRI-002 may work by targeting these proteins or their effects on brain cells. The drug is taken orally as a capsule, making it convenient for patients to use.
Clinical Trial Details
PRI-002 is currently being studied in a clinical trial. Here are some key details about the study:
- It's a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either PRI-002 or a placebo (a substance with no active ingredients), and neither the participants nor the researchers know who is receiving which treatment until the study is over. This design helps ensure the results are not biased.
- The study aims to assess both the safety and efficacy of PRI-002 in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
- The treatment period lasts for 48 weeks (about 11 months), during which participants will receive multiple doses of PRI-002 or placebo.
Eligibility Criteria
To participate in the study, patients must meet certain criteria. Some of the key eligibility requirements include:
- Age between 55 and 80 years
- Diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease
- A Mini-Mental State Examination (MMSE) score between 22 and 30. The MMSE is a test used to measure cognitive impairment.
- Confirmation of Alzheimer's disease diagnosis through specific tests, such as analysis of cerebrospinal fluid (CSF) or a positive amyloid PET scan
There are also certain conditions that would exclude a person from participating, such as having other neurological disorders that could cause cognitive impairment.
Safety and Efficacy Measures
The study will evaluate PRI-002's safety and effectiveness in several ways:
- Safety measures: The researchers will monitor the occurrence of side effects (called adverse events) and any serious adverse events. They will also look for specific brain changes called ARIA-E and ARIA-H (Amyloid-Related Imaging Abnormalities - Edema and Hemorrhage), which have been observed with some other Alzheimer's treatments.
- Efficacy measures: The main measure of effectiveness is the Clinical Dementia Rating-Sum of Boxes (CDR-SB), which assesses cognitive and functional performance. Other tests will look at daily living activities, cognitive function, and changes in biomarkers in the blood and cerebrospinal fluid.
Potential Benefits
While it's important to note that PRI-002 is still in the testing phase and its benefits are not yet proven, the hope is that it could potentially:
- Slow down the progression of Alzheimer's disease symptoms
- Improve or maintain cognitive function and daily living activities in patients with mild cognitive impairment or mild dementia
- Provide a new treatment option for Alzheimer's disease, which currently has limited effective treatments
It's crucial to remember that these potential benefits are still being investigated, and more research is needed to determine the true effectiveness and safety of PRI-002.